We again analyzed in HR+ and HR- subgroups, and in HR-breast tumors, HER2 status affected patients’ DFS, and the DFS curves of HER2-low patients were worse than those of HER2–0 patients, which was statistically different (p=0.027). This evidence concerns the gene ERBB2 and breast neoplasm.